MicroRNAs: Potential biomarkers in cancer

George, Ginu P.; Mittal, Rama Devi

doi:10.1007/s12291-010-0008-z

Cited by 56 publications

(39 citation statements)

References 69 publications

(78 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At present, identification of CSC is the focus of targeted therapy for liver cancer. It has been shown that the cell surface molecular markers of HCSC, including CD133 [9,10], CD90 [11], CD44 [12] and EpCAM [13][14][15], directly or indirectly promote the occurrence of tumors [16]. Studies have shown that miRNAs, endogenous small molecule containing noncoding RNAs that range from approximately 18 to 30 nt in length, have predominant effects In vivo through inhibition of mRNA degradation or translation.…”

Section: Introductionmentioning

confidence: 99%

Characterization of the Role of MicroRNAs in Hepatic Cancer Stem Cells

Daia¹,

Zhang²

2017

Chemotherapy (Los Angel)

View full text Add to dashboard Cite

Liver cancer is one of the most malignant tumors and is prone to relapse, metastasis and drug resistance. These phenomena can be explained by the existence of cancer stem cells (CSCs). CSCs have a strong ability to proliferate, are highly carcinogenic, exhibit multi-directional differentiation, develop drug resistance, and play critical roles in tumor radiotherapy, chemotherapy and tumor recurrence. miRNAs exert effects on oncogenes and tumor suppressor genes. There are distinctive miRNA expression profiles in different types of tumors, and these profiles are closely related to tumorigenesis, differentiation, metastasis and prognosis. Studies have shown that miRNAs are abnormally expressed in hepatocellular carcinoma and have important regulatory effects on the self-renewal and differentiation of hepatic cancer stem cells (HCSCs) as well as on the initiation of tumorigenesis. Therefore, it is critical to understand the impact of miRNAs in HCSC and the associated molecular mechanisms to develop new methods for the clinical diagnosis and treatment of liver cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Characterization of the Role of MicroRNAs in Hepatic Cancer Stem Cells

Daia¹,

Zhang²

2017

Chemotherapy (Los Angel)

View full text Add to dashboard Cite

show abstract

“…Nowadays, aberrantly expressed miRNAs in the cancer patients have attracted a lot of attention among the researchers [10][11][12][13][14]. And accumulative studies have been conducted to confirm whether some specific miRNAs are suitable as biomarkers for GC.…”

Section: Introductionmentioning

confidence: 99%

Hsa-miR-21 and Hsa-miR-29 in Tissue as Potential Diagnostic and Prognostic Biomarkers for Gastric Cancer

Wang

Zhang

Liu

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Gastric cancer (GC) is the fourth most common cancer and the second most common cause of cancer deaths worldwide. Endoscopic examination is the most used method to detect the GC nowadays, whereas this method is expensive and invasive. MicroRNAs (miRNAs) are a group of recently discovered small non-protein-coding RNAs. They regulate the expression of hundreds of target genes; thereby control a wide range of tumorigenic processes. In this study, we selected two miRNAs, hsa-miR-21 and hsa-miR-29, as the targets to assess their diagnostic and prognostic value for GC. Methods: A total of 50 GC patients including 24 females and 26 males were recruited. Tumor and adjacent non-tumor tissue samples were collected from all these participants during the endoscopic examination. RNAs were extracted from these samples, then quantified via qRT-PCR and normalized with RNU43 as the internal control. Statistical analyses were conducted using the GraphPad Prism 5.0. Results: We discovered a higher expression of hsa-miR-21 and a relatively lower expression of hsa-miR-29hsa-miR-29 in the tumor tissue than in the adjacent non-tumor tissue. Moreover, both the two miRNAs showed moderate diagnostic performance (hsa-miR-21: AUC = 0.75, sensitivity = 0.70, specificity = 0.78; hsa-miR-29hsa-miR-29: AUC = 0.73, sensitivity = 0.70, specificity = 0.68). In the follow-up research, we found that higher tissue hsa-miR-21 level was related to a lower overall survival rate, whereas higher tissue hsa-miR-29hsa-miR-29 level was associated with the higher overall survival rate. These results indicated that both hsa-miR-21 and hsa-miR-29 had the potential to be the biomarkers for GC prognosis. Conclusion: In summary, we verified the diagnostic and prognostic value of tissue hsa-miR-21hsa-miR-21 and hsa-miR-29 in GC. Both of them can be potentially applied as novel and non-invasive biomarkers for GC.

show abstract

“…MiR-129-5p may function as a new metastasis-related gene in GC by directly regulating the expression of IL-8. A great number of miRNAs have been identified to be expressed at low levels in tumors, acting as oncogenes, antioncogene, or regulators of cancer stem cells and metastasis [19]. Reduced expression of miR-129 has been found in multiple tumor cell lines and in primary tumors, including GC [7,14,20].…”

Section: Discussionmentioning

confidence: 99%

MiR-129-5p is down-regulated and involved in migration and invasion of gastric cancer cells by targeting interleukin-8

Jiang¹,

Wang²,

Li³

et al. 2016

neo

View full text Add to dashboard Cite

Expression of microRNA-129-5p (miR-129-5p) has been reported to decrease in gastric cancer (GC). However, little information is available about how miR-129-5p affects cell migration and invasion of GC. Cancer samples and matched non-tumor adjacent tissues were obtained from patients with GC. Besides, peripheral blood samples were collected from both the patients and healthy volunteers. Expression of miR-129-5p was analyzed by real-time PCR (RT-PCR). After transfection with miR-129-5p mimics, miR-129-5p inhibitor, or negative controls in human GC cell line SGC-7901, cell viability, colony-formation ability, migration, and invasion assay were evaluated. Luciferase reporter assay, RT-PCR, and enzyme-linked immunosorbent assay (ELISA) were performed to explore whether interleukin-8 was a target of miR-129-5p. Further, small interfering RNA (siRNA) against IL-8 was transfected into cells, and then the effects of miR-129-5p inhibitor on migration and invasion were assessed. MiR-129-5p was down-regulated in both GC samples and blood samples compared to their matched non-tumor adjacent tissues and healthy volunteers (both P < 0.05). Compared to the control group, transfection with miR-129-5p inhibitor markedly increased the cell viability, colony-forming ability, and numbers of migrated and invaded cells. Luciferase reporter assay confirmed that IL-8 was a direct target of miR-129-5p, and IL-8 was negatively regulated by miR-129-5p. Cotransfection of miR-129-5p inhibitor with si-IL-8 reversed the effect of miR-129-5p inhibitor on the migration and invasion of the cells. MiR-129-5p and regulates migration and invasion of GC cells by targeting IL-8.

show abstract

MicroRNAs: Potential biomarkers in cancer

Cited by 56 publications

References 69 publications

Characterization of the Role of MicroRNAs in Hepatic Cancer Stem Cells

Characterization of the Role of MicroRNAs in Hepatic Cancer Stem Cells

Hsa-miR-21 and Hsa-miR-29 in Tissue as Potential Diagnostic and Prognostic Biomarkers for Gastric Cancer

MiR-129-5p is down-regulated and involved in migration and invasion of gastric cancer cells by targeting interleukin-8

Contact Info

Product

Resources

About